Healthcare analysts Arthur Wong and Adam Dibe discuss their quick thoughts on Brexit and what it means for U.S. rated pharma companies. No rating changes at this time, but some concerns on what Brexit may mean for product approval times and research funding.

In this episode, healthcare analyst Matt Todd chats about what is driving the recent positive ratings actions in the contract research organization (CRO) space.

In this episode, healthcare analysts Arthur Wong and Adam Dibe address questions regarding the prospects for Amgen's core portfolio, its drug pipeline, the competition, and its increasing capacity for acquisitions.

In this episode, healthcare analysts Arthur Wong and Adam Dibe discuss the rationale behind our recent rating action on biopharmaceutical company Gilead and field investors' questions concerning the company, including growth expectations and its capacity for acquisitions.

In this episode, healthcare analyst Arthur Wong shares his thoughts on the potential rise of company healthcare exchanges and what impact these entities may have on the pharmaceutical industry and pharmaceutical company ratings.

In this episode, healthcare analyst Arthur Wong discusses our expectations for the ratings on generic drug giant Teva, which is seeking to close its $40.5 billion acquisition of Allergan's generic business. Mr. Wong also fields investors' questions concerning the prospects for Teva's business side and its stance on acquisitions.